Skip to main content

and
  1. Article

    Open Access

    Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

    Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two marker...

    Diar Aziz, Neil Portman, Kristine J. Fernandez, Christine Lee in npj Breast Cancer (2021)